Turing Pharmaceuticals

Photographers take pictures of Martin Shkreli, former chief executive officer of Turing Pharmaceuticals, as he exits federal court with his attorney Benjamin Brafman, left, in the Brooklyn borough of New York on Aug. 4, 2017. Patricia Hurtado. Bloomberg. March 8, 2018 12:58 pm Updated: March 8, 2018 ...

Martin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, center, arrives at federal court in the Brooklyn borough of New York, U.S., on Thursday, June 29, 2017. Shkreli is on trial in Brooklyn, New York, accused of engineering separate frauds tied to his control of two hedge funds he ran as ...

On Monday, the judge ordered Shkreli to forfeit $US7.36 million in assets, which could include Shkreli's $US5 million E-Trade account, stake in the pharmaceutical company Vyera Pharmaceuticals (formerly Turing Pharmaceuticals), the Wu-Tang Clan album Shkreli purchased in 2015, a Lil Wayne album, ...

Pharma bro Martin Shkreli, as then-CEO of Retrophin, launched an unmonitored drug trial without FDA oversight, prosecutors said. The drug was designed to treat the neurodegenerative disease PKAN. Shkreli first gained public notoriety as CEO of Turing Pharmaceuticals, where he raised the price of the ...

The judge said that Shkreli's assets -- a Picasso, $5 million in cash in a personal trading account, a one-of-a-kind special edition album by the Wu-Tang Clan, an unreleased Lil Wayne album and shares in Vyera Pharmaceuticals, formerly Turing Pharmaceuticals -- could be used to meet the forfeiture if ...

The order would allow the government to go after Shkreli's personal property if he doesn't have the cash — including $5 million in a trading account, a one-of-a-kind edition of an album by the Wu-Tang Clan and shares in Vyera Pharmaceuticals, formerly known as Turing Pharmaceuticals, according to ...

FILE PHOTO: Martin Shkreli departs after a hearing at U.S. Federal Court in Brooklyn New FILE PHOTO: Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York, U.S., June 26, 2017.

The judge said that the assets on the table include Shkreli's $A6.45 million E-Trade account, stake in the pharmaceutical company Vyera Pharmaceuticals (formerly Turing Pharmaceuticals), the Wu-Tang Clan album Shkreli purchased in 2015, a Lil Wayne album, an enigma machine, and a Picasso ...

In 2015, one of the main toxoplasmosis drugs, Daraprim, hit the headlines in America after drug manufacturer Turing Pharmaceuticals raised the price from $13.50 to $750 a tablet. Treatments for toxoplasmosis often have serious side effects such as toxicity in the liver and suppression of bone marrow that ...

Shkreli's assets include a Picasso, US$5 million in his personal trading account, a one-of-a-kind special edition album by the Wu-Tang Clan and his shares in Vyera Pharmaceuticals — formerly called Turing Pharmaceuticals, according to prosecutors. Matsumoto's order didn't identify which assets should ...

... Taj Pharmaceuticals Limited and Turing Pharmaceutical. Primary applications of global Drugs for Toxoplasmosis industry includes Acute Toxoplasmosis treatment and Chronic Toxoplasmosis treatment. Different product categories listed in Drugs for Toxoplasmosis market report are Tablet and Injection.

Remember the controversy over the skyrocketing price of the EpiPen, once priced as high as $600 for a pack of two? There are plenty other examples. Who could forget Martin Shkreli, known as “Pharma Bro,” whose Turing Pharmaceuticals bought the U.S. rights to sell Daraprim, a lifesaving medication, ...

FILE PHOTO: Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. ... Bro," raised the price of anti-infection drug Daraprim by over 5,000 percent in 2015 while he was chief executive officer of Turing Pharmaceuticals.

Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York, U.S., June 26, 2017. Lucas Jackson—Reuters. By Chris Morris. 10:36 AM EST. Martin Shkreli can be held responsible for $10.4 ...

Shkreli, 34, best known for raising the price of an AIDS drug by 5,000 percent when he was CEO of Turing Pharmaceuticals, was convicted by a Brooklyn jury in August of defrauding the investors in his hedge funds. Shkreli lied to obtain investors' money then didn't tell them when he made a bad stock bet ...

Shkreli, 34, best known for raising the price of an AIDS drug by 5,000 percent when he was CEO of Turing Pharmaceuticals, was convicted by a Brooklyn jury in August of defrauding the investors in his hedge funds. Shkreli lied to obtain investors' money then didn't tell them when he made a bad stock bet ...

In 2015, the 32-year-old CEO of Turing Pharmaceuticals, Martin Shkreli, increased the price of a critical drug from $13 to $750 a pill. The drug was called Daraprim. It's primarily used to treat parasitic infections. Patients at risk for this infection include those with HIV and cancer. The worst part of this price ...

This list already includes Turing Pharmaceuticals under the management of CEO Martin Shkreli, which raised the price of Daraprim, its anti-parasitic drug, and Mylan Pharmaceuticals under the management of CEO Heather Bresch, which raised the price of its EpiPen, an injectable drug for treatment of ...